Optimal delivery of anthracycline-based chemotherapy in the adjuvant setting improves outcome of breast cancer patients

Breast Cancer Research and Treatment

Volumn 114, Issue 3, 2009, Pages 479-484

  Chirivella, Isabel ^a   Bermejo, Begoña ^a   Insa, Amelia ^a   Pérez Fidalgo, Alejandro ^a   Magro, Ana ^a   Rosello, Susana ^a   García Garre, Elisa ^a   Martín, Paloma ^a   Bosch, Ana ^a   Lluch, Ana ^a  

^a HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

Author keywords

Adjuvant chemotherapy; Anthracycline based; Dose response effect; Non taxane

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; METHOTREXATE;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PATIENT; DISEASE FREE SURVIVAL; DOSE RESPONSE; EARLY CANCER; FEMALE; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ADULT; AGED; ANTHRACYCLINES; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 61449115017     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-008-0018-1     Document Type: Article

References (20)

1. G Bonadonna E Brusamolino P Valagussa 1976 Combination chemotherapy as an adjuvant treatment in operable breast cancer N Engl J Med 294 405 410
2. G Bonadonna A Moliterni M Zambetti 2005 30 years' follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study BMJ 330 217
3. M Martin A Villar A Sole-Calvo 2003 Doxorubicin in combination with fluorouracil and cyclophosphamide (i.v. FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil and cyclophosphamide (i.v. CMF regimen, day 1, 21) as adjuvant chemotherapy for operable breast cancer: a study by the GEICAM group Ann Oncol 14 833 842
4. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) 2005 Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials Lancet 365 1687 1717
5. IC Henderson DF Hayes R Gelman 1988 Dose-response in the treatment of breast cancer: a critical review J Clin Oncol 6 1501 1515
6. G Bonadonna P Valagussa 1981 Dose-response effect of adjuvant chemotherapy in breast cancer N Engl J Med 304 10 15
7. HJ Senn AR Barett-Mahler WF Jungi 1989 Adjuvant chemoimmunotherapy with LMF + BCG in node-negative and node-positive breast cancer patients: 10 year results Eur J Cancer Clin Oncol 25 513 525
8. E Velez-Garcia JT Carpenter Jr M Moore 1992 Postsurgical adjuvant chemotherapy with or without radiotherapy in women with breast cancer and positive axillary nodes: a South-Eastern Cancer Study Group (SEG) Trial Eur J Cancer 28A 1833 1837
9. A Howell RD Rubens H Bush 1984 A controlled trial of adjuvant chemotherapy with melphalan versus cyclophosphamide, methotrexate, and fluorouracil for breast cancer Recent Results Cancer Res 96 74 89
10. DL Ahmann JR O'Fallon PW Scanlon 1982 A preliminary assessment of factors associated with recurrent disease in a surgical adjuvant clinical trial for patients with breast cancer with special emphasis on the aggressiveness of therapy Am J Clin Oncol 5 371 381
11. M Colleoni K Price M Castiglione-Gertsch 1998 Dose-response effect of adjuvant cyclophosphamide, methotrexate, 5-fluorouracil (CMF) in node-positive breast cancer. International Breast Cancer Study Group Eur J Cancer 34 1693 1700
12. H Gurney 2002 How to calculate the dose of chemotherapy Br J Cancer 86 1297 1302
13. GH Lyman DC Dale J Crawford 2003 Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices J Clin Oncol 21 4524 4531
14. DR Budman 2004 Dose and schedule as determinants of outcomes in chemotherapy for breast cancer Semin Oncol 31 3 9
15. P Poikonen C Blomqvist H Joensuu 2001 Effect of obesity on the leukocyte nadir in women treated with adjuvant cyclophosphamide, methotrexate, and fluorouracil dosed according to body surface area Acta Oncol 40 67 71
16. GL Rosner JB Hargis DR Hollis 1996 Relationship between toxicity and obesity in women receiving adjuvant chemotherapy for breast cancer: results from cancer and leukemia group B study 8541 J Clin Oncol 14 3000 3008
17. M Colleoni S Li RD Gelber 2005 Relation between chemotherapy dose, oestrogen receptor expression, and body-mass index Lancet 366 1108 1110
18. PJ Goodwin NF Boyd 1990 Body size and breast cancer prognosis: a critical review of the evidence Breast Cancer Res Treat 16 205 214
19. WC Wood DR Budman AH Korzun 1994 Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma N Engl J Med 330 1253 1259
20. C Redmond B Fisher HS Wieand 1983 The methodologic dilemma in retrospectively correlating the amount of chemotherapy received in adjuvant therapy protocols with disease-free survival Cancer Treat Rep 67 519 526